Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Notes from Friedland's Interview:
1. "It's fascinating....The news announcement on Monday... a full patent application was filed with the US Patent office to replace the original patent on this claim. A lot of people have topical products out there But OWCP's psoriasis cream has undergone a huge amount of trials in Israel, and Israel is 95% of Cannabis research in the world.
2. Mark Leibovit: "OWC had many products on the pipeline, this psoriasis cream is just one of many."
3. Friedland: "Yes... the one I am most fascinated about is that OWC is doing some ore clinical work for Multiple Myloma. Nothing right now conventionally kills multiple myloma cancer cells and the preliminary results that they did with mice, in 60% of the mice, 100% of the Multiple Myloma cells were killed. It's not human trials but those are quite significant. What people have to understand about OWCP is that it's a pharmaceutical development company. They have to also understand that OWCP is about the Cannabis space in Israel and its scientists - and that's keys. OWC and it's management team over there are incredibly plugged into what's happening in Israel, which is leading edge on Pharma development worldwide.
4. Leibovit: "Jeff Friedland has been involved with the Cannabis space in Israel and USA (including cultivation facilities and dispensaries ie Colorado) for a long time."
5. Friedland: "I am delighted to be involved in the space in Israel, USA and Canada. I love this space. Israel is an emerging market."
6. Leibovit: "I am very excited too and the Médical Marijuana space offers a great opportunity for investors and helps a lot of people. This was not a paid interview, this was my love for the space."
Yes sir, we are setting ourselves up here for an Epic run!
This is a good site if you want to compare apples to apples with OWCP and GWP$. And come to your own conclusion. Without a doubt they are a leader and ahead of the game in this industry, but I feel OWCP will have patents and products that will make them a strong second in 2018 and beyond.
https://www.newcannabisventures.com/gw-pharmas-powerful-patent-portfolio/
Ha ha I can't wait:)
Gwp$ has very little revenue, so if they do it's not much or meaningful. There stock price is due to some patents they have and there predicted $1 billion market for epilepsy, plus they have a good deal of cash on hand.
I think They do have a few other products there working on in clinical trials.
Long story short, MM moving to orphan drug alone will give us a market cap like there's. Throw the cream, ptsd, fibromyalgia, sublingual tablet in the mix and what are we worth in 2018-2020???
Take a decent position here folks and hold, be comfortable with what you own, and don't listen to the noise behind the curtains.
We would be equivalent to around $20 a share to have an equal market cap with GWP$. We are only talking cream here, not the sublingual tablet and MM. The Tablet will be an amazing success story as Europe and other countries will not allow smokable MMJ treatments. OWCP longterm has amazing potential. We are not dependent on what the US gov. Decides to do with mmj, one of the few companies out there that can say that!
It's meant for psoriasis, but an announcement of more uses for the cream will be in the future. It will soon be like duct tape, bandaids, peroxide, etc. a necessity in every household............what's should the market cap be then???? We are looking at a billion dollar product here with all the uses.
My thoughts exactly:)
Europe, Canada, and then California will be the first state named to sell cream. Then India and China where it really gets awesome. All this in probably the next 12 months....
I'm not really seeing what the problem is:)
Great longterm investment here, best of luck to all as great things are underway, we are well ahead of most mmj bio pharma companies by years!
Gary, the sublingual tablet is developed and will be following up this push to get cream to hospitals in countries with legal MMJ.
Will this be used to treat ptsd and fibromyalgia in your opinion since we are doing studies on them? I honestly am looking at there cream and MM study all the time so I feel it's something I and others are almost overlooking as a pretty big catalyst, one of many for the next 6 months.
Multi dollars longterm, that's the big thing! MM STUDY IS HEATING UP!
They could file For orphan drug as early as end of this quarter after testing the best delivery system, oral or Rectum for MM.
Johnson & Johnson will be helping pay for the trials, they have a big interest in MM and the two sides are talking.
Let me be the voice of reason through some of what seems like chaos at best on this board.
The facts are :
1. the cream
OWCP started pre clinical study for the cream on 11/2016
ONLY 8 months later they have :
* Amazing results - reported
* first ever IRB approval for safety study
* full IP filed with all countries that have MMJ program/ bill , an asset that less than handful MMJ companies have .
Lead to product market ready
* the best possible EU rep
2. They have completed the development of a sublingual tablet
3. They have moved one step further with MM study
All according to there business plan, not I-hubs
I think that For an outside observant this is one of a kind biopharmaceutical company .
Markets react to good news 6 months ahead typically, although I'm not sure if that applies on OTC Land. Upon announcement of where it will be sold and through who, you will already want your position IMO
Cream sales and sublingual tablet sales look like they both will start in Germany and spread through Europe. One of the few, maybe only Mmj bio pharma to have a product and capability of not relying on what happens in the US regarding MMJ. Let's throw announcement of more uses for the cream on skin and it could easily turn into a billion dollar product. Not today, tomorrow, but in the next year, maybe 2 it could. What's the pps worth then? That's just the cream, not the tablet or announcement of moving MM to orphan drug. Longterm this will prevail, short term we remain vulnerable due to no sales announcements of our cream.
Without a doubt we are vulnerable until the cream hits the shelves.
First in Germany and a few other countries the way its looking. Them countries alone will put revenue in the millions of dollars. Also when they announce other uses for the cream you can probably double, triple, quadruple revenue. Yes, it's tough watching this slide, but it has more to do with the whole sector rather then OWCP plan to run the company. Once sales begin we can start separating ourselves from the sector.
Mario bought in this morning so it's going to crash til he gets back out!!
I agree, but it's definite progress! The longterm future here is is getting brighter!
This is getting real here long and newbies! Buyout potential here increases monthly!
Frieland mentioned MM study on Wall Street raw! We will wake up one morning and hear it's heading to orphan drug! Think of the lives that will change!
Ha ha, she's a great asset to our MM study isn't she! When I seen she was part of it I was simply ecstatic. She's been searching for the best MM drug for years and has connections to big pharma.
OWCP doesn't really care what I-hub speculates. They are sticking to there business plan and we are all about to find out it's a good one! High level talks happening for cream sales as we speak!
JUST SO YOU ALL UNDERSTAND HERE. Medique is contracted as a " middle man" to penetrate the German Market. They are also contracted to get sales going in all of Europe. They are based in Germany and Tel Aviv.
It's important to understand that there legislation in Europe does not allow smokable mmj... period! So that means our cream, and sublingual tablet is a prime product For sales in Europe! We will eventually be crosslisting to European stock exchanges so we are less affected by what our American Government decides to do with MMJ. This is well over $4 to $7 dollar stock when sales get rolling and over a $10 pps when MM moves to orphan drug!
PETACH TIKVA, Israel, May 31, 2017 /PRNewswire/ --
OWC Pharmaceutical Research Corp. (OTC: OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market.
(Logo: http://mma.prnewswire.com/media/458036/OWC_Logo.jpg )
Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets. mediq's objectives for OWCP will consist of both scientific collaboration and most importantly the development of a commercial market for OWCP's proprietary, active cannabinoid-based topical psoriasis cream in Germany.
Commenting on the collaboration with OWCP, Jan Wende, managing director of mediq stated, "We're looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany. Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP's proprietary cannabinoid-based topical psoriasis cream is the right product at the right time. Furthermore, Germany is the largest European healthcare market and therefore offers the perfect platform to gain local evidence and roll out the concept into other European countries. Our initial focus for OWCP is on the German market, however we're excited about the long-term opportunities throughout Europe, a market with a population of over 740 million."
Alon Sinai, managing director of OWCP's wholly-owned, Israel-based subsidiary, One World Cannabis, also commented on the collaboration with mediq, "The German market is a great opportunity for OWCP. Germany, with its population of over 81 million, and a gross domestic product of over US$3.36 trillion is the largest economy in Europe. Also, potentially beneficial to OWCP is Germany's recent medical cannabis legislation, which currently limits the usage of smokable-products, and which also provides for reimbursement for medical cannabis by the country's healthcare system. mediq is a great partner for OWCP, and we're looking forward to the prospects of a long-term and mutually relationship with the company both regarding the introduction of OWCP's cannabinoid-based psoriasis cream in the German marketplace, but also for the prospects for scientific collaboration in the country."
I'm only speculating here, but with the MM study ending this quarter with how to best treat a patient, through oral or a suppository. Wouldn't it seem if successful that's the last piece to enter it into orphan drug? Like we could be hearing it's moving to Orphan drug in Q4 this year?
I think we should be hearing something with there fibromyalgia and ptsd studies also. There sublingual tablet will be huge for that! Nobody really talks about them study's on this board, but they are progressing. Them studies to could help generate revenue in 2018 and beyond!
He's being sarcastic
MM study has been kept somewhat hush hush by OWCP to keep competitors at bay. One day we will wake up and hear it's moving to orphan drug! That's going to be happening sooner then later! They've recruited all the right DR's in February now to there advisory board to help this process along!
It will be like peroxide or duct tape, a needed household item:)
Neither, just collects a paycheck.... google his name, then google mine and let me know the results..... bet you don't find me:)
We are about to be in business here, explosive times are ahead!
We are good here.... great news is on its way here for July!
Email Sheba and ask them, then post there response.
The sooner you all realize this is a longterm play the easier it will be to hold it!
It's easy to buy and sell a stock, it's hardest to hold it!
$4 to $7 pps coming up. Sheba holds a bit of royalties for the patent process and is partially how they will be reimbursed for there R&D.
PRETTY DANG THRIFTY OWCP IS!!!
Yes, Cherry there are lots of sideline investors at the moment. I've recently had good discussions with owcp and am pleased with where we are heading. Europe and Canada are big areas to begin sales, and less complicated then the US! We are on the right track!
I agree Kraken, Ive been saying $4 to $7 pps is likely and not far out! Buy, accumulate, and hold!
There's a lot of catalyst coming up!
CREAM SALES
MORE CLINICAL STUDIES ON USES FOR THE CREAM
MM DELIVERY SYSTEM STUDY ENDS THIS QUARTER
MM POSSIBLE ORPHAN DRUG STATUS ANNOUNCED
SUBLINGUAL TABLET DEALS ANNOUNCED
FIBROMYALGIA ANNOUNCEMENT STUDY ON GOING WITH UPDATE COMING
This company will really get things rolling here over the course of the next few months and beyond.!